Genmab A/S (Copenhagen: GEN), a biotechnology company specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer, reported on Tuesday that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD432m in Q1 2018.

Also, net sales were USD264m in the US and USD168m in the rest of the world.

Reportedly, Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license with Janssen Biotech Inc to develop, manufacture and commercialise DARZALEX.

Daratumumab is being developed by Janssen Biotech, Inc under an exclusive worldwide license to develop, manufacture and commercialise daratumumab from Genmab. A comprehensive clinical development programme for daratumumab is ongoing, including multiple phase III studies in smouldering, relapsed and frontline multiple myeloma settings and in amyloidosis.

Additional studies are also ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases, such as NKT-cell lymphoma, myelodysplastic syndromes, B and T-ALL and selected solid tumours.

Daratumumab has received two Breakthrough Therapy Designations from the US FDA for multiple myeloma, as both a monotherapy and in combination with other therapies.